Logo for Impel Pharmaceuticals Inc

Impel Pharmaceuticals Investor Relations Material

Latest events

Logo for Impel Pharmaceuticals Inc

Q1 2023

Impel Pharmaceuticals
Logo for Impel Pharmaceuticals

Q3 2023

14 Nov, 2023
Logo for Impel Pharmaceuticals

Q2 2023

18 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Impel Pharmaceuticals Inc

Access all reports
Impel Pharmaceuticals Inc, develops therapies for patients with central nervous system diseases in the United States. The company is developing INP104 (dihydroergotamine mesylate), a drug candidate that is in Phase III clinical study for the treatment of cluster headache; and INP107 (sumatriptan) Nasal Powder, which has completed Phase I testing designed to investigate its safety, tolerability, pharmacokinetics, and delivery. Its product candidates are also developed for the treatment of migraine headache and pain associated with chronic sinusitis. The company was founded in 2015 and is headquartered in Seattle, Washington.